BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+44.3%
5Y CAGR+63.9%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+44.3%/yr
vs +93.4%/yr prior
5Y CAGR
+63.9%/yr
Recent deceleration
Acceleration
-49.2pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
11.8x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $19.80M | +58.6% |
| 2024 | $12.48M | +167.9% |
| 2023 | $4.66M | -29.3% |
| 2022 | $6.59M | -9.2% |
| 2021 | $7.26M | +333.4% |
| 2020 | $1.68M | -59.1% |
| 2019 | $4.10M | +770.7% |
| 2018 | $471000.00 | -72.3% |
| 2017 | $1.70M | -36.9% |
| 2016 | $2.70M | - |